Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adia MedADIA 14 EV-to-FCF is -68.01 as of Aug. 01, 2026. GuruFocus rates ADIA with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 406 Healthcare Providers & Services companies, Adia Med ranks worse than 246305.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adia Med's Enterprise Value is $14.83 Mil.
Adia Med's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.22 Mil. Therefore, Adia Med's EV-to-FCF for today is -68.01.
The historical rank and industry rank for Adia Med's EV-to-FCF or its related term are showing as below:
ADIA'
s EV-to-FCF Range Over the Past 10 Years
Min: -119.1 Med: -23.75 Max: -6.47
Current: -68.01
During the past 2 years, the highest EV-to-FCF of Adia Med was -6.47. The lowest was -119.10. And the median was -23.75.
ADIA's EV-to-FCF is ranked worse than 100% of 406
companies
in the Healthcare Providers & Services industry
Industry Median: 17.83
vs ADIA: -68.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adia Med's share price for today is $0.149.
Adia Med's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Adia Med EV-to-FCF Related Terms
Adia Med EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Adia Med's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Adia Med's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adia Med EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Adia Med's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Adia Med's EV-to-FCF falls into.
Adia Med's current Enterprise Value is $14.83 Mil.
Adia Med's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adia Med (ADIA) has a EV-to-FCF of -68.01 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adia Med and its competitors. According to the industry distribution chart, Adia Med ranks #999999 out of 406 companies in the Healthcare Providers & Services industry.
Is Adia Med's EV-to-FCF too high?
Adia Med's current EV-to-FCF is -68.01. Based on the distribution chart, Adia Med ranks #999999 out of 406 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Adia Med has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's EV-to-FCF compare to GBCS and CCM?
According to the Healthcare Providers & Services industry distribution chart, Adia Med ranks #999999 out of 406 companies for EV-to-FCF. This places Adia Med in the lower half of its industry. The industry median EV-to-FCF is 17.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.83, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adia Med and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adia Med's current EV-to-FCF is -68.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current EV-to-FCF of -68.01. The current EV-to-FCF is -68.01. Adia Med's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Adia Med (ADIA), the current EV-to-FCF is -68.01 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
14GF Score
Get the complete analysis for ADIA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIA has been successfully added to your 
